| abstract |
The present invention relates to a compound which inhibits the activity of BTK (bruton tyrosine kinase) and / or JAK3 (Janus tyrosine kinase 3), a pharmaceutical composition thereof, a use thereof in pharmaceuticals, a method of inhibiting BTK and / or JAK3 activity And to methods of treating and / or preventing a disease or condition mediated by BTK and / or JAK3 of a mammal (particularly a human) using the same. The compound has the structural formula I. Equation I |